Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Khouri, Issa F. [1 ]
Saliba, Rima M. [1 ]
Ledesma, Celina [1 ]
Jabbour, Elias J. [2 ]
Turturro, Francesco [3 ]
Alatrash, Gheath [4 ]
Ahmed, Sairah [1 ]
Oran, Betul [1 ]
Patel, Krina K. [1 ]
Olson, Amanda [4 ]
Marin, David [1 ]
Popat, Uday R. [1 ]
Suki, Tina S. [1 ]
Jorgensen, Jeffrey L. [5 ]
Medeiros, L. Jeffrey [5 ]
Gulbis, Alison M. [6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Gladstone, Douglas
    Andre, Marc
    Jan Zaucha
    Assouline, Sarit
    Bellam, Naresh
    Cascavilla, Nicole
    Jourdan, Eric
    Panwalkar, Amit
    Patti, Caterina
    Schulte, Clemens
    Zaja, Francesco
    Goswami, Trishna
    Elgeioushi, Nairouz
    Streicher, Katie
    Bao, Haifeng
    Spaner, David
    BLOOD, 2014, 124 (21)
  • [22] ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCEND
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Jurcza, Wojciech
    HAEMATOLOGICA, 2020, 105 : 205 - 206
  • [23] Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S220 - S221
  • [24] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [25] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
  • [26] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [27] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [28] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [29] Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia
    Weide, Rudolf
    Mergenthaler, Ulrike
    Friesenhahn, Vera
    Kleboth, Kristina
    Heymanns, Jochen
    Thomalla, Joerg
    Koeppler, Hubert
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1468 - 1474
  • [30] EARLY RESULTS OF A PHASE II STUDY ADDING PERI-TRANSPLANT RITUXIMAB TO NONMYELOABLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS (PTS) WITH HIGH-RISK FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Sorror, M. L.
    Storer, B.
    Sandmaier, B. M.
    Chauncey, T.
    Bruno, B.
    Andersen, N. N. S.
    Hogan, W. J.
    Storb, R.
    Maloney, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S289 - S290
12345